Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts.
Tumor response may be assessed readily by the use of Response Evaluation Criteria in Solid Tumor version 1.1. However, the criteria mainly depend on tumor size changes. These criteria do not reflect other morphologic (tumor necrosis, hemorrhage, and cavitation), functional, or metabolic changes that may occur with targeted chemotherapy or even with conventional chemotherapy. The state-of-the-art multidetector CT is still playing an important role, by showing high-quality, high-resolution images that are appropriate enough to measure tumor size and its changes. Additional imaging biomarker devices such as dual energy CT, positron emission tomography, MRI including diffusion-weighted MRI shall be more frequently used for tumor response evaluation, because they provide detailed anatomic, and functional or metabolic change information during tumor treatment, particularly during targeted chemotherapy. This review elucidates morphologic and functional or metabolic approaches, and new concepts in the evaluation of tumor response in the era of personalized medicine (targeted chemotherapy).
Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea.
Hee
H
Kang
Ho Yun
HY
Lee
Kyung Soo
KS
Lee
Jae-Hun
JH
Kim
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003952:Diagnostic Imaging / Q000592:standards / Q000639:trends; D005544:Forecasting; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D017063:Outcome Assessment, Health Care; D017410:Practice Guidelines as Topic; D057285:Precision Medicine; D011871:Radiology / Q000592:standards / Q000639:trends; D014944:World Health Organization
D000970:Antineoplastic Agents